biostudies-literatureUnknown21(1)Wang M<h4>Study objectives</h4>Cannabidiol (CBD) is increasingly used as a health supplement, though few clinical studies have demonstrated benefits. The primary objective of this study was to evaluate the effects of an oral CBD-terpene formulation on sleep physiology in individuals with insomnia.<h4>Methods</h4>In this double-blind, placebo-controlled, randomized clinical trial, 125 individuals with insomnia received an oral administration of CBD (300 mg) and terpenes (1 mg each of linalool, myrcene, phytol, limonene, α-terpinene, α-terpineol, α-pinene, and β-caryophyllene) for ≥ 4 days/wk over 4 weeks using a crossover design. The study medication was devoid of Δ⁹-tetrahydrocannabinol. The primary outcome measure was the percentage of time participants spent in the combination of slJournal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine69-80https://www.ebi.ac.uk/biostudies/studies/S-EPMC11701282biostudies-literatureEffects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study.PMC11701282Wang MClark JIFaust MChang EStella NPatel VAbbott SMuchowski PJfalseEffects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study.<h4>Study objectives</h4>Cannabidiol (CBD) is increasingly used as a health supplement, though few clinical studies have demonstrated benefits. The primary objective of this study was to evaluate the effects of an oral CBD-terpene formulation on sleep physiology in individuals with insomnia.<h4>Methods</h4>In this double-blind, placebo-controlled, randomized clinical trial, 125 individuals with insomnia received an oral administration of CBD (300 mg) and terpenes (1 mg each of linalool, myrcene, phytol, limonene, α-terpinene, α-terpineol, α-pinene, and β-caryophyllene) for ≥ 4 days/wk over 4 weeks using a crossover design. The study medication was devoid of Δ⁹-tetrahydrocannabinol. The primary outcome measure was the percentage of time participants spent in the combination of sl2025-01-01T00:00:00Z2025 Jan2026-06-13T04:52:27.635Z2026-06-13T03:09:15.715ZS-EPMC117012823916742110.5664/jcsm.11324